eligibility_summary
Adults ≥18 with untreated, PET+ follicular lymphoma grade 1–3a, measurable disease, meet GELF, ECOG 0–2, adequate marrow/renal/hepatic function, tumor tissue for diagnosis/EZH2. Exclude: grade 3b or transformed FL, prior systemic therapy, malabsorption, CNS disease, active serious infection (HBV/HCV/HIV CD4<200), recent immunosuppression, autoimmune disease needing treatment, prior allo-SCT, major cardiac/pulmonary disease, live vaccines, pregnancy, drug hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in untreated follicular lymphoma testing: 1) Tazemetostat—oral small-molecule EZH2 inhibitor (epigenetic therapy). Mechanism: inhibits EZH2 histone methyltransferase (reduces H3K27me3), suppressing germinal center B-cell lymphoma proliferation and potentially enhancing antitumor immunity. 2) Mosunetuzumab—subcutaneous CD20×CD3 bispecific T-cell–engaging antibody, step-up dosing, redirects patient T cells via CD3 to lyse CD20+ B-cell lymphoma. Target cells/pathways: EZH2-driven epigenetic program in malignant B cells, CD20 on B cells, CD3 on T cells, promoting immune synapse formation and T-cell cytotoxicity.